Abacavir

Drugs

Volumn 55, Issue 5, 1998, Pages 729-736

  Foster, R H ^a   Faulds, D ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ARTICLE; ASTHENIA; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CROSS RESISTANCE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; LYMPHOCYTE COUNT; MALAISE; META ANALYSIS; RASH; VIRUS INHIBITION; VIRUS LOAD;

EID: 0031900668     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199855050-00018     Document Type: Article

References (33)

1. 1. BG Gazzard GJ Moyle J Weber 1997 British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals Lancet 349 1086 92 10.1016/S0140-6736(96)12073-0 Gazzard BG, Moyle GJ, Weber J, et al. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997 Apr 12; 349: 1086–92
2. 2. CCJ Carpenter MA Fischl SM Hammer 1997 Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society — USA Panel JAMA 277 24 1962 9 9200638 10.1001/jama.1997.03540480062040 1:STN:280:DyaK2szksVWisw%3D%3D Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society — USA Panel. JAMA 1997 Jun 25; 277(24): 1962–9
3. 3. SM Daluge SS Good MB Faletto 1997 1592U89, A novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity Antimicrob Agents Chemother 41 5 1082 93 9145874 1:CAS:528:DyaK2sXjtVCnu78%3D Daluge SM, Good SS, Faletto MB, et al. 1592U89, A novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother 1997 May; 41(5): 1082–93
4. 4. MH St Clair J Millard J Rooney 1996 In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents Antiviral Res 29 53 6 8721545 10.1016/0166-3542(95)00916-7 1:STN:280:DyaK283otlOgtA%3D%3D St Clair MH, Millard J, Rooney J, et al. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antiviral Res 1996 Jan; 29: 53–6
5. 5. M Tisdale T Alnadaf D Cousens 1997 Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89 Antimicrob Agents Chemother 41 5 1094 8 9145875 1:CAS:528:DyaK2sXjtVCnu7w%3D Tisdale M, Alnadaf T, Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother 1997 May; 41(5): 1094–8
6. 6. Mellors JW, Hertogs K, Peeters F, et al. Susceptibility profile (Antivirogram™) of 943 clinical HTV-1 isolates to abacavir (1592U89) [poster no. 687]. Fifth Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago (IL)
7. 7. Palmer S, Shafer R, Merigan TC. Highly drug-resistant fflV-l isolates are cross resistant to many of the current anti-HIV compounds in clinical development [abstract]. Fifth Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago (IL)
8. 8. Limoges J, Persidky Y, Rasmussen J, et al. 1592 prevents viral spread in brain tissue of SCID mice with HIV-1 encephalitis [abstract]. Fifth Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago (IL)
9. 9. Zimmerman TP, Mahony WB, Domin BA, et al. Membrane permeation characteristics of the structurally related anti-HIV agents 1592U89 and (−)-carbovir in human erythrocytes and human T-lymphoblastoid CD4+ CEM cells [abstract no. 109]. Antiviral Res 1995 Mar; 26: A283
10. 10. MB Faletto WH Miller EP Garvey 1997 Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89 Antimicrob Agents Chemother 41 5 1099 107 9145876 1:CAS:528:DyaK2sXjtVCnu70%3D Faletto MB, Miller WH, Garvey EP, et al. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob Agents Chemother 1997 May; 41(5): 1099–107
11. 11. Good SS, Owens BS, Faletto MB, et al. Disposition in monkeys and mice of (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (1592U89) succinate, a potent inhibitor of HIV [abstract no. 186]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994 Oct 4–7; Orlando (FL), USA, 92
12. 12. McDowell JA, Symonds WT, Kumar PN, et al. Initial phase I study of anti-HIV agent 1592U89 in a single-dose escalation design including food effect and dosage form evaluation [abstract no. 1109]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17–20; San Francisco, USA, 224
13. 13. McDowell JA, Symonds WT, LaFon SW. Single-dose and steady-state pharmacokinetics of escalating regimens of 1592U89 with and without zidovudine [abstract no. Mo.B.1140]. XI International Conference on AIDS; 1996 Jul 7–12; Vancouver, Canada, 79
14. 14. Hughes W, McDowell J, Adams L, et al. Evaluation of the novel nucleoside 1592U89 in a phase I safety and pharmacokinetics (PK) study in HIV-infected infants and children [abstract no. 332]. 3rd Conference on Retroviruses and Opportunistic Infections; 1996 Jan 28–Feb 1; Washington, DC, USA; 115
15. 15. Ravitch JR, Jarrett JL, White HR, et al. Central nervous system penetration of the antiretroviral abacavir (1592) in human and animal models [poster no. 636]. Fifth Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago (IL)
16. 16. McDowell JA, Sadler BM, Millard J, et al. Evaluation of potential pharmacokinetic (PK) drug interaction between 141W94 and 1592U89 in HIV+ patients [abstract no. A-62]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, Ontario, Canada, 13
17. 17. Ravitch JR, Walsh JS, Reese MJ, et al. In vivo and in vitro studies of the potential for drug interactions involving the antiretroviral abacavir (1592) in humans [poster no. 634]. Fifth Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago (IL)
18. 18. WT Symonds J McDowell G Chittick 1996 The safety and pharmacokinetics of GW1592U89, zidovudine and lamivudine (3TC) alone and in combination after single-dose administration in HIV-infected patients [abstract no. P19] AIDS 10 2 S23 Symonds WT, McDowell J, Chittick G, et al. The safety and pharmacokinetics of GW1592U89, zidovudine and lamivudine (3TC) alone and in combination after single-dose administration in HIV-infected patients [abstract no. P19]. AIDS 1996 Nov; 10 Suppl. 2: S23
19. 19. A Sonnerborg D Lancaster R Torres 1996 The safety and antiviral effect of 1592U89, alone and in combination with zidovudine in HIV-1 infected patients with CD4+ counts 200–500 cells/mm3 [abstract no. OP4.1] AIDS 10 2 S12 Sonnerborg A, Lancaster D, Torres R, et al. The safety and antiviral effect of 1592U89, alone and in combination with zidovudine in HIV-1 infected patients with CD4+ counts 200–500 cells/mm3 [abstract no. OP4.1]. AIDS 1996 Nov; 10 Suppl. 2: S12
20. 20. Early results suggest potential for new combination of investigational anti-HIV drugs [media release]. 1997 Jan 26; PR Newswire; http://www.newspage.com
21. 21. Bart PA, Rizzardi GP, Gallant S, et al. Combination abacavir (1592)/amprenavir (141 W94) therapy in HIV-1-infected antiretroviral-naive subjects with CD4+ counts >400 cells/µL and viral load >5000 copies/ml [poster no. 365]. Fifth Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago (IL)
22. 22. Kost R, Cao Y, Vesanen M, et al. Combination therapy with abacavir (1592), 141W94, and AZT/3TC in subjects acutely and chronically infected with HIV-1 [abstract]. Fifth Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago (IL)
23. 23. Prins J, Jurriaans S, Roos M, et al. An attempt at maximally suppressive anti-HIV therapy [abstract]. Fifth Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago (IL)
24. 24. Investigational anti-HIV compound abacavir (1592) with individual HIV protease inhibitors results in potent antiretroviral activity [media release]. 1998 Feb 2; PR Newswire; http://www.prnewswire.com
25. 25. Mellors J, Lederman M, Haas D, et al. Antiretroviral effects of therapy combining abacavir (1592) with HIV protease inhibitors (PIs) [abstract]. Fifth Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago (IL)
26. 26. Lederman M, Mellors J, Haas D, et al. Early T-lymphocyte responses to antiretroviral therapy with abacavir (1592, ABC) and HIV protease inhibitors (PI) [poster no. 364]. Fifth Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago (IL)
27. 27. Lanier ER, Stone C, Griffin P, et al. Phenotypic sensitivity to abacavir (1592, ABC) in the presence of multiple genotypic mutations; correlation with viral load response [poster no. 686]. Fifth Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago (IL)
28. 28. Danehower S, Lanier ER, Hetherington S, et al. A phase I study of 1592 in HIV-infected infants and children: viral and phenotypic analysis [abstract]. Fifth Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago (IL)
29. 29. Data on file, Glaxo Wellcome, 1998
30. 30. Staszewski S, Katlama C, Harrer T, et al. Preliminary long-term open-label data from patients using abacavir (1592, ABC)-containing antiretroviral treatment regimens [poster no. 658]. Fifth Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago (IL)
31. 31. Torres R, Saag M, Lancaster D, et al. Antiviral effects of abacavir (1592) following 48 weeks of therapy [poster no. 659]. Fifth Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago (IL)
32. 32. Saag M, Lancaster D, Sonnerborg A, et al. A phase I/II study of a novel nucleoside reverse transcriptase inhibitor, 1592U89 monotherapy vs 1592U89 + zidovudine (ZDV) or placebo in HIV infected patients with CD4 counts 200–500/mm 3 [abstract no. 195]. 3rd Conference on Retroviruses and Opportunistic Infections; 1996 Jan 28–Feb 1; Washington, DC, USA, 89
33. 33. Kline MW, Blanchard S, Shenep JL, et al. A phase I study of 1592U89 in HIV-infected infants and children [abstract]. Fifth Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago (IL)